CARLSBAD, Calif., May 7, 2024
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a
clinical-stage biotechnology company focused on developing
next-generation precision medicines that target large opportunities
in Fibroblast Growth Factor Receptor (FGFR) biology, today
announced changes to its Board of Directors with the appointments
of Susan Moran, M.D., M.S.C.E. and
S. Michael Rothenberg, M.D., Ph.D.
as independent directors, and the resignation of Isan Chen, M.D. The changes are effective
immediately.
"Susan and Michael's impressive careers will provide TYRA with
valuable guidance as we advance our potential next-generation
precision candidates toward people in need. We have a unique
opportunity to develop TYRA-300 for skeletal dysplasias and
oncology, which aligns well with Susan and Michael's extensive
expertise in FGFR3 biology. Susan led the development and approval
of infigratinib and Michael is an experienced oncologist who led
the successful development of several targeted oncology drugs while
at Loxo Oncology and Pfizer," said Todd
Harris, CEO of TYRA.
Dr. Moran has over 20 years of industry and academic experience,
successfully leading clinical trials from Phase 1 to Phase 3, as
well as overseeing NDA and MAA submissions for various
investigational products, including the successful approval of
Nerlynx. Dr. Moran most recently served as the Chief Medical
Officer of RayzeBio, a clinical-stage radiopharmaceutical
therapeutics company (acquired by Bristol Meyers Squibb in
February 2024). Prior to RayzeBio,
she was Chief Medical Officer of QED Therapeutics, an affiliate of
BridgeBio Pharma, where she oversaw the clinical development of
infigratinib, leading to approval of Truseltiq. Before QED, Dr.
Moran was VP and Head of Clinical Development at Puma Biotechnology
and previously held senior positions at Takeda (previously
Millennium) and Sanofi (former Genzyme). Dr. Moran has played roles
in the development, registration, and post-marketing support of
products for a number of solid tumors, including bile duct,
urothelial, and liver cancer, among others, as well as multiple
sclerosis, achondroplasia, and other disorders. She is a
board-certified internist and has served on the faculty of the
University of Pennsylvania School of
Medicine and Harvard Medical School.
Dr. Moran received her B.A. from the University of Virginia, M.D. from Duke University, and M.S. in Clinical Epidemiology
from the University of Pennsylvania
School of Medicine. Dr. Moran currently serves on the board of
directors of BioAtla, Inc., a clinical-stage biotechnology
company.
"I am pleased to join as a director of TYRA at this important
phase in the Company's maturation," said Dr. Moran. "I look forward
to leveraging my experience in achondroplasia and oncology, and
working with the Board and accomplished management team to
contribute to the future success of TYRA."
Dr. Rothenberg is a trained oncologist who brings two
decades of clinical care and drug development experience across
multiple therapeutic modalities to the TYRA board spanning target
identification through approval. Dr. Rothenberg currently serves as
the Chief Medical Officer of insitro, a machine learning-powered
drug discovery and development company, where he leads all aspects
of clinical development. Prior to insitro, he was vice president of
early oncology development and clinical research at Pfizer, where
he oversaw Pfizer's oncology and hematology early clinical
development portfolio, advancing more than 20 first-in-patient
clinical trials, including supervising elranatamab (Elrexfio™, a
bispecific antibody) through the first-in-human trial to human
proof-of-concept. Prior to Pfizer, he was Vice President of
Research and Development at Loxo Oncology, where he led early
clinical development for novel, targeted anticancer therapies,
including the approved RET inhibitor RETEVMO® (selpercatinib). He
previously served as a medical oncologist and researcher focused on
targeted therapeutics at Massachusetts
General Hospital. Dr. Rothenberg received his B.A. from
Yale University and his M.D. and Ph.D.
from Stanford University.
Dr. Rothenberg added, "TYRA has an exceptional in-house
precision medicine platform, and I am excited about the clinical
potential of its pipeline. I am thrilled to join the Board and look
forward to utilizing my experience as an oncologist and targeted
drug developer to help TYRA navigate its next stages of
growth."
In connection with these appointments, Dr. Chen, who has served
as a director since June 2020, has
resigned from the TYRA Board. "On behalf of the Board, I want to
thank Isan for his many contributions to TYRA. Isan played an
important role as an original investor and supported the initial
development of our technology and pipeline," said Robert More, Chairman of the TYRA Board.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage
biotechnology company focused on developing next-generation
precision medicines that target large opportunities in FGFR
biology. The Company's in-house precision medicine platform, SNÅP,
enables rapid and precise drug design through iterative molecular
SNÅPshots that help predict genetic alterations most likely to
cause acquired resistance to existing therapies. TYRA's initial
focus is on applying its accelerated small molecule drug discovery
engine to develop therapies in targeted oncology and genetically
defined conditions. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people,
please visit www.tyra.bio and engage with us on LinkedIn.
Forward-Looking Statements
TYRA cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. The forward-looking statements are
based on our current beliefs and expectations and include, but are
not limited to: the potential to develop next-generation precision
medicines and the opportunity to develop TYRA-300 for
achondroplasia and oncology. Actual results may differ from those
set forth in this press release due to the risks and uncertainties
inherent in our business, including, without limitation: we are
early in our development efforts, have only recently begun testing
TYRA-300 and TYRA-200 for oncology in clinical trials and the
approach we are taking to discover and develop drugs based on our
SNÅP platform is novel and unproven and it may never lead to
product candidates that are successful in clinical development or
approved products of commercial value; potential delays in the
commencement, enrollment, data readouts and completion of
preclinical studies and clinical trials; results from preclinical
studies or early clinical trials not necessarily being predictive
of future results; our dependence on third parties in connection
with manufacturing, research and preclinical testing; acceptance by
the FDA of INDs or of similar regulatory submissions by comparable
foreign regulatory authorities for the conduct of clinical trials
of TYRA-300 in pediatric achondroplasia; unexpected adverse side
effects or inadequate efficacy of our product candidates that may
limit their development, regulatory approval, and/or
commercialization; and other risks described in our prior filings
with the Securities and Exchange Commission (SEC), including under
the heading "Risk Factors" in our annual report on Form 10-K and
any subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and we undertake no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-appointments-of-susan-moran-md-msce-and-s-michael-rothenberg-md-phd-to-its-board-of-directors-302138779.html
SOURCE Tyra Biosciences